Boston—Although anti-HIV drug regimens
have had a profound impact on preventing mother-to-child transmission of HIV,
researchers have been grappling with the potential health consequences of
a treatment strategy commonly used in resource-poor countries for that purpose.
Findings presented here at the 12th Annual Retrovirus Conference provide new
evidence regarding some potential risks of this regimen—which consisted
of a single dose of nevirapine during labor to the mother and a single dose
to the newborn during the first 3 days after delivery—as well as some
early evidence showing potential benefits from alternative regimens.
Stephenson J. Reducing HIV Vertical Transmission Scrutinized. JAMA. 2005;293(17):2079-2081. doi:10.1001/jama.293.17.2079